Playback speed
10 seconds
Dacomitinib: Dark Horse EGFR TKI Charges into First Line Setting for Advanced NSCLC
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
142 views
November 2, 2018
Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with ...
read more ↘ dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting?
↖ read less
read more ↘ dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting?
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung